Retatrutide vs Sermorelin: prices, identity and regulatory status (2026)
Retatrutide and Sermorelin are different research compounds, not substitutes for each other: Retatrutide is a single compound (C221H342N46O68); Sermorelin is a 29-amino-acid peptide (C149H246N44O42S). Neither product has a current in-stock price right now. Retatrutide has no Drugs@FDA application; Sermorelin was FDA-approved but every application is discontinued.
Research use only. These are research-use-only listings sold for laboratory research, not prescription medicines and not for human use. PeptideTech does not compare effects or provide dosing information.
Retatrutide vs Sermorelin: current prices and packages
| Compared property | Retatrutide | Sermorelin |
|---|---|---|
| Category | GLP-1 | Growth hormone |
| Compared package | 30mg | 5mg |
| Lowest current price | No current in-stock price | No current in-stock price |
| Price per labelled mg | — | — |
| Package sizes | 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 48mg, 50mg, 60mg | 2mg, 5mg, 10mg, 15mg |
| Vendors with current prices | 0 | 0 |
| Form at this package | No listing | No listing |
| Stock | Out of stock | Out of stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | Retatrutide | Sermorelin |
|---|---|---|
| Molecular formula | C221H342N46O68 | C149H246N44O42S |
| Molecular weight | 4731 g/mol | 3357.9 g/mol |
| Sequence | — | H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (29 residues) |
| CAS Registry Number | — | 86168-78-7 |
| Registered clinical trials | 34 (11 active) · Phase 3: 14, Phase 2: 4, Phase 1: 15 | None recorded |
| Human intervention studies | 7 | 2 |
| US regulatory status | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search | FDA-approved as Geref, all applications discontinued (NDA 019863 and NDA 020443; checked October 7, 2026)DiscontinuedGEREF · NDA 019863 · 1990GEREF · NDA 020443 · 1997Research listings are not these medicines. |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
Retatrutide
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 2024
Sermorelin
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. The Journal of clinical endocrinology and metabolism, 1996
- A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement, 1993
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Research-use listings for each compound
Research-use-only listings sold for laboratory research, not prescription medicines and not for human use.
Retatrutide
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence.
No vendor has a current in-stock price for this package.
Retatrutide prices →Price history →Sermorelin
Sermorelin is a catalogue entry whose compound-specific reference review has not yet been completed.
No vendor has a current in-stock price for this package.
Sermorelin prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price, except that the labelled featured partner, LA Peptides, is pinned first; “Cheapest” always marks the lowest price. PeptideTech earns a commission when you buy through a link.
Full method →